Studies performed during the past 2 years have provided a deeper understanding into the role of CTLA-4, which is expressed ... additional peripheral regulatory mechanisms ensure that the ...

However, the major impediments to effective immunotherapy are a series of negative immunoregulatory safety mechanisms that ... cytotoxic T-lymphocyte antigen-4 (CTLA-4) [46], a negative co ...

It is a drug that binds to the protein CTLA-4 to help immune cells kill ... TAK-500 has three possible mechanisms of action: activation of IFN response, reprogramming of suppressive intratumoral ...

Botensilimab is a human Fc enhanced CTLA-4 blocking antibody designed to boost both innate and adaptive anti-tumor immune responses. Its novel design leverages mechanisms of action to extend immun ...

CS2009's mechanism of action ... CS2009 showed stronger anti-tumour effects than both PD-1/CTLA-4 and PD-1/VEGF bispecific antibodies; and in toxicology studies, CS2009 exhibited a safety margin ...

is a human Fc enhanced CTLA-4 blocking antibody designed to boost both innate and adaptive anti-tumor immune responses. Its novel design leverages mechanisms of action to extend immunotherapy ...